Mesothelioma - Healing Genes


Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

A Phase I Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Phase 1


Doctors at Memorial Sloan Kettering in New York and New Jersey are recruiting patients with certain cancers to participate in a clinical trial of gene-modified autologous (from the patient back to themself) T-cell transplant. The therapy removes T-cells from the body and genetically modifies them in the lab to target the mesothelioma cancer cells, multiplies them, and then re-infuses them to the patient either alone or after a round of chemotherapy. The therapy will require up to a year-long follow-up.

These cancers are eligible for the investigatory treatment:

  • Malignant Pleural Disease
  • Mesothelioma
  • Metastases
  • Lung Cancer
  • Breast Cancer


  • Be age 18 years or older
  • Have a diagnosis of one of the eligible cancers
  • Not have central nervous system metastasis


  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Have blood drawn, immune cells separated and blood cells returned (leukapheresis)
  3. After lab modification time (3 to 6 weeks), the patient will admit to the hospital and receive chemotherapy, if assigned to that group of the study.
  4. The gene-edited immune cells will be infused and drugs to help promote their growth injected.
  5. Recovery in the hospital for several weeks.
  6. Follow up over the course of the following year.


The study will take place at Memorial Sloan Kettering Cancer Center. Map.


Prasad Adusumilli, MD  |  212-639-8093

Marjorie Zauderer, MD  |  646-888-4656



Memorial Sloan Kettering Cancer Center

Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader